{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"All-causality SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Treatment-related SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. Treatment-related SAEs were determined by the investigator.","groups":[{"description":"Participants received SC administration of azacitidine daily at a dose of 75 mg/m2/day on Days 1-7 of every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD. In Cycle 1 only, administration of glasdegib commenced on Day 2 of the cycle (C1D2) to permit DDI evaluation.","id":"OG000","title":"Lead-in Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety analysis population included all participants who received at least 1 dose of any study treatment.","reportingStatus":"POSTED","timeFrame":"maximum of approximately 15 months","title":"Number of Participants With Serious Adverse Events (SAEs) in the LIC","type":"PRIMARY","unitOfMeasure":"Participants"}